SC 13G/A: ACHIEVE LIFE SCIENCES, INC.

Ticker: ACHV · Form: SC 13G/A · Filed: May 20, 2024 · CIK: 949858

Achieve Life Sciences, Inc. SC 13G/A Filing Summary
FieldDetail
CompanyAchieve Life Sciences, Inc. (ACHV)
Form TypeSC 13G/A
Filed DateMay 20, 2024
Risk Levellow
Pages6
Reading Time8 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sc-13g-a

AI Summary

SC 13G/A filing by ACHIEVE LIFE SCIENCES, INC..

Risk Assessment

Risk Level: low

FAQ

What type of filing is this?

This is a SC 13G/A filing submitted by Achieve Life Sciences, Inc. (ticker: ACHV) to the SEC on May 20, 2024.

What is the risk level of this SC 13G/A filing?

This filing has been assessed as low risk.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti).

How long is this filing?

Achieve Life Sciences, Inc.'s SC 13G/A filing is 6 pages with approximately 1,940 words. Estimated reading time is 8 minutes.

Where can I view the full SC 13G/A filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,940 words · 8 min read · ~6 pages · Grade level 8.5 · Accepted 2024-05-20 17:01:27

Key Financial Figures

  • $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

(a)

Item 1(a). Name of Issuer: Achieve Life Sciences, Inc. ("Issuer")

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 22722 29th Drive SE, Suite 100, Bothell, WA 98021 1040 West Georgia Street, Suite 1030, Vancouver, British Columbia, Canada V6E 4H1

(a)

Item 2(a). Name of Persons Filing: The names of the persons filing this statement on Schedule 13G are (collectively, the "Reporting Persons"): Contrarian Achieve SPV LP, a Delaware limited partnership ("Contrarian Achieve"); Contrarian Alpha, LP, a Delaware limited partnership ("Contrarian Alpha"); Contrarian Achieve GP LLC, a Delaware limited liability company ("Achieve GP"); Contrarian Alpha GP, LLC, a New York limited liability company ("Alpha GP"); Contrarian Alpha Management, LLC, a New York limited liability company ("Contrarian Alpha Management"); and Parker Quillen, a United States citizen ("Mr. Quillen");

(b)

Item 2(b). Address of Principal Business Office or, if None, Residence: The principal business address of each of the Reporting Persons is 22 Fieldview Lane, East Hampton, NY 11937.

(c)

Item 2(c). Citizenship: Contrarian Achieve is a Delaware limited partnership Contrarian Alpha is a Delaware limited partnership Achieve GP is a Delaware limited liability company Alpha GP is a New York limited liability company Contrarian Alpha Management is a New York limited liability company Mr. Quillen is a citizen of the United States.

(d)

Item 2(d). Title of Class of Securities: Common Stock, par value $0.001 per share (the "Common Stock")

(e)

Item 2(e). CUSIP Number: 004468500 Item 3. If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Exchange Act. (b) [ ] Bank as defined in Section 3(a)(6) of the Exchange Act. (c) [ ] Insurance company defined in Section 3(a)(19) of the Exchange Act. (d) [ ] Investment company registered under Section 8 of the Investment Company Act. (e) [ ] Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) [ ] Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) [ ] Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) [ ] Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) [ ] Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) [ ] Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J). (k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ Item 4. (a) Amount beneficially owned: As of May 15, 2024: Contrarian Achieve beneficially owned a total of 1,978,377 shares of Common Stock consisting of 1,318,918 shares of Common Stock held directly and warrants currently exercisable for 659,459 shares of Common Stock. Contrarian Alpha beneficially owned a total of 325,000 shares of Common Stock consisting of 225,000 shares of Common Stock held directly and warrants currently exercisable for 100,000 shares of Common Stock. Achieve GP, as the general partner of Contrarian Achieve, may be deemed to beneficially own the total of 1,978,377 shares of Common Stock beneficially owned by Contrarian Achieve. Alpha GP, as the general partner of Contrarian Alpha, may be deemed to be

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this Dated: May 20, 2024 CONTRARIAN ACHIEVE SPV LP By: Contrarian Achieve GP LLC, its general partner By: /s/ Parker Quillen Parker Quillen, Manager CONTRARIAN ALPHA LP By: Contrarian Alpha GP, LLC, its general partner By: /s/ Parker Quillen Parker Quillen, Manager CONTRARIAN ACHIEVE GP LLC By: /s/ Parker Quillen Parker Quillen, Manager CONTRARIAN ALPHA GP, LLC By: /s/ Parker Quillen Parker Quillen, Manager CONTRARIAN ALPHA MANAGEMENT, LLC By: /s/ Parker Quillen Parker Quillen, Manager /s/ Parker Quillen PARKER QUILLEN

View Full Filing

View this SC 13G/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.